Weekly profile.CYTRX CORP. Symbol: CYTR Exchange: NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on Close: $2.03 1-WK % Chg: 10.3% Business Overview CytRx Corporation, incorporated in 1985, is a ribonucleic acid (RNA) interference (RNAi) and biopharmaceutical company focused on the development and commercialization of human therapeutics. The Company is engaged in developing products based on advanced RNAi technology for the human healthcare market. The technology essentially uses RNA to selectively turn off the harmful genes of infectious viruses or malignant tumor cells. CytRx has a broad-based strategic alliance with the University of Massachusetts Medical School UMMS is ranked fourth in primary care education among the nation’s 125 medical schools in the 2006 U.S.News & World Report annual guide, “America’s Best Graduate Schools”. UMMS is also a major center for research. (UMMS) that has given the Company unparalleled access to RNAi technology and serves as a platform for a myriad of drug discovery applications, including obesity, Type II diabetes Type II diabetes Type II diabetes is the most common form of diabetes and usually appears in middle aged adults. It is often associated with obesity and may be delayed or controlled with diet and exercise. Mentioned in: Diabetic Ketoacidosis and ALS (Lou Gehrig's disease Lou Geh·rig's disease n. See amyotrophic lateral sclerosis. ). CytRx formed a subsidiary to develop orally active, small molecule drugs and has research programs at UMMS and Massachusetts General Hospital Massachusetts General Hospital Health care The major teaching hospital for Harvard Medical School, widely regarded as one of the best health care centers in the world to develop therapies for ALS. Income Statement 2003 * 2002 Summary Revenue ($0.1) ($1.1) Headquarters: Los Angeles Operating Income (9.7) (2.9) Market Cap: $68.42 million Net Income (11.4) (6.2) Dividend Yield: NA ** Eps ($0.47) ($0.39) P/E Ratio: NA *** * LTM period ended on 9/30/03 ** Company does not pay a dividend *** Company is not profitable [GRAPHIC OMITTED |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion